Avalyn Pharma closed at $26.67 on Nov 5, down 2.91%, 23.8% below its highest close since Sep 11. Volume of 476.7K shares was 1.14× its 20-day average (close to normal).
Split-adjusted performance: +4.5% over one month.
Short interest was 2.4M shares at the Oct 15 settlement, down 6.4% from the prior report (11.6% of float, 6.6 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −28.4%, revenue growth +5.9%, net margin −38.9%, P/E 15.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| AVLNAvalyn Pharma | $26.67 | −2.91% | — | — | — | — | $1.18B | |
| AMPHAmphastar Pharmaceuticals | $27.66 | −1.28% | +15.1% | +5.4% | 16.5% | 15.0 | $1.18B | Compare |
| MNKDMannkind | $3.76 | −4.33% | +5.9% | +42.9% | −17.4% | — | $1.21B | Compare |
| VSTMVerastem | $9.38 | −4.77% | +65.7% | +1775.4% | −86.5% | — | $1.14B | Compare |
| LBRXLB Pharmaceuticals | $38.09 | −6.76% | +19.1% | — | — | — | $1.23B | Compare |
| NKTRNektar Therapeutics | $36.15 | −6.06% | −56.6% | −9.3% | −401.0% | — | $1.23B | Compare |
| OMEROmeros | $17.07 | −6.11% | +16.6% | — | 46.4% | 9.9 | $1.24B | Compare |
| URGNUroGen Pharma | $25.73 | −10.47% | −3.2% | +199.2% | −19.8% | — | $1.26B | Compare |
| SPTXSeaport Therapeutics | $20.39 | −2.72% | — | — | — | — | $1.09B | Compare |
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
